Cohort studycited by the Tayebat archiveabstract only checked A-INS-11 standard review

Diabetes drugs and cancer deaths in Canada

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Overview

Bowker SL et al.. Diabetes Care 2006 · PMID 16443869 · DOI 10.2337/diacare.29.02.06.dc05-1558

Insulin users had more cancer deaths than metformin users, possibly due to other differences.

Does the study support the specific claim? Partly · Methodological quality: low

Study explained simply

What did the researchers want to find out?: Antidiabetic therapy and cancer mortality
How was the study done?: Population-based cohort (Saskatchewan Health)
How many people, animals or samples were studied?: 10,309; New users of metformin or sulfonylureas
What was actually found?: aHR 1.9 for insulin.
How large was the observed effect?: aHR 1.9 (1.5-2.4)
What do the results mean in everyday life?: Association, cause unknown.
What are the study's limitations?: No BMI/smoking; Confounding
What does it say about Elawady's specific claim?: Association for C-INS-05; C-ODD-11.
Do the results apply to Germany and Europe?: Canadian data.
What can explicitly not be concluded from this study?: Causation.

Antidiabetic therapy and cancer mortality

Study design: Cohort study – Population-based cohort (Saskatchewan Health)
Population: New users of metformin or sulfonylureas
Country: Canada
Period: 1991-1996, follow-up to 1999
Sample size: 10,309
Inclusion and exclusion criteria: As described in the abstract; details not available in abstract.

Results: Cancer mortality 4.9% SU, 3.5% metformin, 5.8% insulin users. SU vs metformin aHR 1.3 (1.1-1.6); insulin aHR 1.9 (1.5-2.4).
Absolute risks: not reported
Authors' conclusion: Increased cancer mortality with sulfonylureas and insulin vs metformin; uncertain whether harm, metformin protection, or unmeasured factors.

Association only.

Association for C-INS-05; C-ODD-11.

Canadian data.

Hypothesis-generating.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	low
Risk of bias	high
Precision of results	moderate
Directness	direct
Reproducibility	partly replicated
Consistency with the overall evidence	inconsistent
Regional transferability	moderate
Adequacy of the interpretation (by the archive)	partly correct but over-interpreted

None beyond those stated.

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: Listed in the archive bibliography for 'insulin-injections' without its own interpretation; used as general support for the claim that insulin intensification harms.
A. What was actually studied?: Antidiabetic therapy and cancer mortality
B. What did the authors find?: aHR 1.9 for insulin.
C. What conclusions do the authors themselves draw?: Increased cancer mortality with sulfonylureas and insulin vs metformin; uncertain whether harm, metformin protection, or unmeasured factors.
D. What does the archive derive from it?: Support for insulin-cancer link.
E. Is this derivation scientifically justified?: Not as causal evidence; authors list alternative explanations.
Adequacy of the interpretation (by the archive): partly correct but over-interpreted